Table 4.

Incidence of treatment-related adverse events attributed to avelumab.

	Cabozantinib 20 mg plus avelumab (n = 3)		Cabozantinib 40 mg plus avelumab (n = 3)		Cabozantinib 60 mg plus avelumab (n = 6)		Total (n-=12)
Adverse events, n (%)	Any grade	Grades 3-5	Any grade	Grades 3-5	Any grade	Grades 3-5	Any grade	Grades€ 3-5
Diarrhea			1 (33.3)		3 (50)	2 (33.3)	4 (33.3)	2 (16.7)
Acute kidney injury					2 (33.3)	1 (16.7)	2 (16.7)	1 (8.3)
Fatigue			2 (66.7)		2 (33.3)	1 (16.7)	4 (33.3)	1 (8.3)
Allergic rhinitis					1 (16.7)		1 (8.3)
Colitis					1 (16.7)		1 (8.3)
Hypercalcemia					1 (16.7)	1 (16.7)	1 (8.3)	1 (8.3)
Hypocalcemia					1 (16.7)	1 (16.7)	1 (8.3)	1 (8.3)
Palmar-plantar erythrodysesthesia syndrome	1 (33.3)		1 (33.3)		1 (16.7)		3 (25)
Pruritus	1 (33.3)				1 (16.7)		2 (16.7)
Skin hyperpigmentation					1 (16.7)		1 (8.3)
Anorexia			1 (33.3)				1 (8.3)
Cough			1 (33.3)				1 (8.3)
Dry skin	1 (33.3)						1 (8.3)
Dysgeusia			1 (33.3)				1 (8.3)
Hypothyroidism	1 (33.3)		1 (33.3)				2 (16.7)
Plantar Fascitis	1 (33.3)						1 (8.3)
Rash maculopapular			3 (100)	1 (33.3)			3 (25)	1 (8.3)
Face lesions			1 (33.3)				1 (8.3)
Skin hypopigmentation	1 (33.3)						1 (8.3)

€ = there were no grade 5 events in any patient.